secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001819790-24-000015
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q4 XDEMVY sales $13.1M; positive Phase 2a rosacea data
-------------------------------------------------------------

- XDEMVY net product sales $13.1M in Q4, $14.7M total since late-August launch; >17,400 bottles dispensed.
- Positive Phase 2a Galatea trial for TP-04 in papulopustular rosacea: statistically significant improvements in lesions and IGA score vs vehicle at Week 12.
- Q4 net loss $41.9M ($1.31 EPS); full-year net loss $135.9M ($4.62 EPS).
- Cash, equivalents and marketable securities $227.4M as of Dec 31, 2023.
- ~6,000 ECPs have started patients on XDEMVY; >50% prescribed to multiple patients as of Feb 23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000015/0001819790-24-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000015/tars-20240227.htm
  HTML page:      https://secwatch.observer/filing/0001819790-24-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer